Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-02

Clinical Trial Update: Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function [Phase 1]

View source ↗

Summary

Phase 1 study assessing oral lasmiditan in participants with normal and impaired renal function; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2019-12-02